Focus on Biologics
Katherine T. Adams

The implementation of the Affordable Care Act is expected to push the FDA into issuing a final rule, and several states have already considered the issue of biologic substitution. The cost advantage is incontrovertible, but will doctors and patients join reference product manufacturers in trying to restrict them?